Longeveron Inc.

Shares of biotech company $LGVN continue to surge today after yesterdays big move, when the company released Phase 2 trial data of Lomocel-B, a treatment for patients suffering from hypoplastic left heart syndrome.

Share This Article

 

About the Author

Longeveron Inc.

Joey Ramson